Stock Analysis

Some Analysts Just Cut Their DBV Technologies S.A. (EPA:DBV) Estimates

The analysts covering DBV Technologies S.A. (EPA:DBV) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for this year. This report focused on revenue estimates, and it looks as though the consensus view of the business has become substantially more conservative.

Following the downgrade, the most recent consensus for DBV Technologies from its eight analysts is for revenues of €14m in 2020 which, if met, would be a sizeable 46% increase on its sales over the past 12 months. Losses are presumed to reduce, shrinking 12% from last year to €3.64. Yet prior to the latest estimates, the analysts had been forecasting revenues of €17m and losses of €3.63 per share in 2020. So there's definitely been a change in sentiment in this update, with the analysts administering a substantial haircut to this year's revenue estimates, while at the same time holding losses per share steady.

Check out our latest analysis for DBV Technologies

ENXTPA:DBV Earnings and Revenue Growth July 1st 2020
ENXTPA:DBV Earnings and Revenue Growth July 1st 2020

There was no real change to the consensus price target of €18.27, suggesting that the revisions to revenue estimates are not expected to have a long-term impact on DBV Technologies' valuation. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. The most optimistic DBV Technologies analyst has a price target of €30.70 per share, while the most pessimistic values it at €8.70. As you can see the range of estimates is wide, with the lowest valuation coming in at less than half the most bullish estimate, suggesting there are some strongly diverging views on how think this business will perform. As a result it might not be possible to derive much meaning from the consensus price target, which is after all just an average of this wide range of estimates.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the DBV Technologies' past performance and to peers in the same industry. The analysts are definitely expecting DBV Technologies' growth to accelerate, with the forecast 46% growth ranking favourably alongside historical growth of 16% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 29% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect DBV Technologies to grow faster than the wider industry.

Advertisement

The Bottom Line

Unfortunately, analysts also downgraded their revenue estimates, although our data indicates revenues are expected to perform better than the wider market. Given the stark change in sentiment, we'd understand if investors became more cautious on DBV Technologies after today.

As you can see, the analysts clearly aren't bullish, and there might be good reason for that. We've identified some potential issues with DBV Technologies' financials, such as major dilution from new stock issuance in the past year. For more information, you can click here to discover this and the 1 other flag we've identified.

Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are downgrading their estimates. So you may also wish to search this free list of stocks that insiders are buying.

If you’re looking to trade DBV Technologies, open an account with the lowest-cost* platform trusted by professionals, Interactive Brokers. Their clients from over 200 countries and territories trade stocks, options, futures, forex, bonds and funds worldwide from a single integrated account.Promoted


New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020


Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.

About ENXTPA:DBV

DBV Technologies

A clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France.

Adequate balance sheet with slight risk.

Advertisement

Weekly Picks

WE
WealthAP
PYPL logo
WealthAP on PayPal Holdings ·

The "Sleeping Giant" Stumbles, Then Wakes Up

Fair Value:US$8227.1% undervalued
12 users have followed this narrative
1 users have commented on this narrative
8 users have liked this narrative
WO
BMBL logo
woodworthfund on Bumble ·

Swiped Left by Wall Street: The BMBL Rebound Trade

Fair Value:US$960.0% undervalued
5 users have followed this narrative
0 users have commented on this narrative
4 users have liked this narrative
WE
WealthAP
DUOL logo
WealthAP on Duolingo ·

Duolingo (DUOL): Why A 20% Drop Might Be The Entry Point We've Been Waiting For

Fair Value:US$268.6433.4% undervalued
16 users have followed this narrative
2 users have commented on this narrative
2 users have liked this narrative

Updated Narratives

BA
NVO logo
bactrian on Novo Nordisk ·

A Quality Compounder Marked Down on Overblown Fears

Fair Value:US$9540.8% undervalued
95 users have followed this narrative
8 users have commented on this narrative
1 users have liked this narrative
YI
ETSY logo
yiannisz on Etsy ·

Etsy Stock: Defending Differentiation in a World of Infinite Marketplaces

Fair Value:US$64.454.7% undervalued
4 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
YI
ALGN logo
yiannisz on Align Technology ·

Align Technology Stock: Premium Orthodontics in a Cost-Sensitive World

Fair Value:US$154.628.4% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

AG
Agricola
EXN logo
Agricola on Excellon Resources ·

A case for CA$31.80 (undiluted), aka 8,616% upside from CA$0.37 (an 86 bagger!).

Fair Value:CA$31.898.3% undervalued
69 users have followed this narrative
10 users have commented on this narrative
20 users have liked this narrative
AL
RKLB logo
AlexLovell on Rocket Lab ·

Early mover in a fast growing industry. Likely to experience share price volatility as they scale

Fair Value:US$16.25429.4% overvalued
71 users have followed this narrative
1 users have commented on this narrative
18 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$253.0226.0% undervalued
1020 users have followed this narrative
6 users have commented on this narrative
28 users have liked this narrative